Serum Level of Soluble Receptor for Advanced Glycation End Products in Asthmatic Children and its Correlation to Severity and Pulmonary Functions

Elseify, Magda Y.; Fouda, Eman; Nabih, Enas Samir

doi:10.7754/clin.lab.2013.130418

Cited by 20 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the patients in the study of Sukkar et al (20) were clinically stable older asthmatics, and 68% of them used inhaled corticosteroids; in the present study, all the patients were newly-diagnosed asthmatics, suggesting that plasma sRAGE levels, although altered in different asthma inflammatory phenotypes, may remain relatively stable regardless of medical therapy. Similar to the findings adults (7,11,16,20), Eli-Seify et al (33) reported that children with >2% eosinophils and ≥40% neutrophils exhibited lower sRAGE levels compared with children with >2% eosinophils and <40% neutrophils; this suggests that the sRAGE level may remain relatively stable in different asthma inflammatory phenotypes regardless of age.…”

Section: Discussionsupporting

confidence: 69%

“…Previous studies have demonstrated that decreased plasma levels in sRAGE were associated with increased progression of airflow limitations in patients with COPD patients and asthmatic children (24,33). However, Watanabe et al (11) and Zhou et al (31) observed that sRAGE levels were not associated with asthma severity in adult patients with asthma, possibly as their patients were all non-neutrophilic asthmatics.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Decreased soluble RAGE in neutrophilic asthma is correlated with disease severity and RAGE G82S variants

Lyu

Zhao

et al. 2017

Mol Med Report

View full text Add to dashboard Cite

The advanced glycosylation end product-specific receptor (RAGE) has been demonstrated to be an important mediator of asthma pathogenesis. The soluble isoform of RAGE (sRAGE) acts as a 'decoy' to sequester RAGE ligands, and thus prevents their binding to the receptor. A number of reports have linked deficiency of sRAGE to the severity and outcomes of various human diseases, and association with RAGE G82S variants. However, whether sRAGE levels are increased or decreased in asthmatic patients is unclear. The aim of the present study was to determine plasma sRAGE levels in different asthma phenotypes and associations of plasma sRAGE levels with RAGE G82S variants. A total of 85 neutrophilic and 109 non‑neutrophilic newly diagnosed asthmatic patients, and 118 healthy controls, were recruited. Plasma sRAGE levels were measured by ELISA analysis. RAGE G82S genotypes were detected using the Sanger sequencing method. Plasma sRAGE levels were decreased in neutrophilic asthmatics (443.67±208.9 pg/ml) and increased in non‑neutrophilic asthmatics (677.63±300.75 pg/ml) compared with healthy controls (550.02±300.83 pg/ml) (P<0.001). Plasma sRAGE levels were positively correlated with FEV1% predicted (FEV1% Pre) (rp=0.258; P=0.023) in neutrophilic asthmatics. The frequency of G82S genotypes was significantly different between neutrophilic and non‑neutrophilic asthmatics (P=0.009). Neutrophilic asthmatics with genotypes A/G or A/A (389.83±150.37 and 264.59±161.74 pg/ml, respectively) had significantly decreased sRAGE levels compared with the G/G genotype (498.64±235.37 pg/ml) (P=0.022). Those with the A/G and A/A genotype (60.14±22.36%) displayed a trend toward lower FEV1% Pre compared with those with the G/G genotype (64.51±27.37%). No significant difference in sRAGE levels or an association with FEV1% Pre was observed between the different genotypes in non‑neutrophilic asthmatics. In conclusion, the results of the present study indicated that plasma sRAGE levels are altered in different asthma inflammatory phenotypes. Plasma sRAGE may be a biomarker of asthma severity and may be associated with G82S gene variants in neutrophilic asthmatics.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 96%

Decreased soluble RAGE in neutrophilic asthma is correlated with disease severity and RAGE G82S variants

Lyu

Zhao

et al. 2017

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…Protein glycosylation, as the most common form of posttranslational modification, with as many as 70% of all human proteins estimated glycosylated15, can better and more sensitively reflect the body inflammation16, cancer1718, diabetes19, asthma20, and some physiological changes21, due to the structural diversity, micro-heterogeneity, and variability22. For example, serum alpha-fetoprotein (AFP) has long been used as a diagnostic marker for hepatocellular carcinoma (HCC), however the value of AFP in HCC diagnosis has recently been challenged due to its significant rates of false positive and false negative findings.…”

mentioning

confidence: 99%

Serum glycopattern and Maackia amurensis lectin-II binding glycoproteins in autism spectrum disorder

Qin

Chen

Yang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The pathophysiology of autistic spectrum disorder (ASD) is not fully understood and there are no diagnostic or predictive biomarkers. Glycosylation modified as many as 70% of all human proteins can sensitively reflect various pathological changes. However, little is known about the alterations of glycosylation and glycoproteins in ASD. In this study, serum glycopattern and the maackia amurensis lectin-II binding glycoproteins (MBGs) in 65 children with ASD and 65 age-matched typically developing (TD) children were compared by using lectin microarrays and lectin-magnetic particle conjugate-assisted LC-MS/MS analyses. Expression of Siaα2-3 Gal/GalNAc was significantly increased in pooled (fold change = 3.33, p < 0.001) and individual (p = 0.009) serum samples from ASD versus TD children. A total of 194 and 217 MGBs were identified from TD and ASD sera respectively, of which 74 proteins were specially identified or up-regulated in ASD. Bioinformatic analysis revealed abnormal complement cascade and aberrant regulation of response-to-stimulus that might be novel makers or markers for ASD. Moreover, increase of APOD α2-3 sialoglycosylation could sensitively and specifically distinguish ASD samples from TD samples (AUC is 0.88). In conclusion, alteration of MBGs expression and their sialoglycosylation may serve as potential biomarkers for diagnosis of ASD, and provide useful information for investigations into the pathogenesis of ASD.

show abstract

“…Another experimental study [15] has shown that RAGE is more expressed in asthmatic airways and giving RAGE inhibitors markedly decreased inflammation in animal model of asthma. El-Seify et al [16] found that Serum level of sRAGE correlated with severity of bronchial asthma clinically and functionally.…”

Section: Discussionmentioning

confidence: 98%

Receptor of advanced glycation end products in childhood asthma exacerbation

Bediwy

Hassan

Rushdy

2016

Egyptian Journal of Chest Diseases and Tuberculosis

View full text Add to dashboard Cite

Background: Receptor of advanced glycation end products (RAGE) is a new marker of inflammation in different inflammatory disorders. Bronchial asthma as an inflammatory disease is associated with increased levels of many markers of inflammation which are used to evaluate the severity of childhood asthma, and may be the targets of new therapeutic options aiming at improving the management of such diseases.Aim: To evaluate serum levels of RAGE in acute asthma exacerbation in children, and also to correlate their levels with peak expiratory flow rate (PEFR) and number of exacerbations during the last 6 months.Methods: One hundred asthmatic children, aged 6-12 years, with acute exacerbation were evaluated during their visit to ER unit for serum RAGE (measured by ELISA) and PEFR before receiving any treatment. They were 53 males and 47 females. Fifty subjects were taken as controls for serum RAGE.Results: Serum RAGE was significantly higher in asthmatic children compared to control group. It was higher in asthmatic children who had poor response to initial therapy at emergency room. Serum RAGE showed significant negative correlation with PEFR and significant positive correlation with a number of asthma exacerbations during the last 6 months.Conclusion: Serum RAGE is elevated during acute asthma exacerbation in children. High levels above 1733.5 pg/mL can expect poor response to initial therapy at emergency room and need for hospitalization with sensitivity and specificity and a specificity of 90.5% and 83.35% respectively.

show abstract

Serum Level of Soluble Receptor for Advanced Glycation End Products in Asthmatic Children and its Correlation to Severity and Pulmonary Functions

Cited by 20 publications

References 0 publications

Decreased soluble RAGE in neutrophilic asthma is correlated with disease severity and RAGE G82S variants

Decreased soluble RAGE in neutrophilic asthma is correlated with disease severity and RAGE G82S variants

Serum glycopattern and Maackia amurensis lectin-II binding glycoproteins in autism spectrum disorder

Receptor of advanced glycation end products in childhood asthma exacerbation

Contact Info

Product

Resources

About